Scopio Labs Raises $10M to Advance AI Blood Analyzer

Scopio Labs, an AI-driven healthtech company, has raised an additional US$10 million in its Series D funding round, led by Viola Growth, bringing its total funding to US$52 million.

The funds will be used to accelerate the development of its flagship product — the Complete Blood Morphology (CBM) analyzer, an innovative AI-powered system designed to automate the analysis of peripheral blood smears. The CBM analyzer aims to transform hematology diagnostics by addressing one of the field’s core challenges: the manual, labor-intensive, and expertise-dependent nature of blood smear analysis.

Key Highlights

Scopio Labs secures $10M from Viola Growth in Series D round
Funds will support development of AI-powered CBM blood analyzer
CBM system to be unveiled at ADLM 2025; approval still pending

By leveraging artificial intelligence and high-resolution imaging, Scopio's technology seeks to make blood diagnostics faster, more accessible, and more scalable, particularly in under-resourced settings.

However, the CBM system is still under development and has not yet been approved for in vitro diagnostic use. Scopio Labs plans to demonstrate the analyzer at the ADLM 2025 Annual Conference in Chicago later this month, providing a first look at its capabilities to the clinical laboratory community.

Also Read: Israeli Startups Set to Secure $6.25 Million in Incubator Funding

This funding and upcoming showcase position Scopio Labs as a potential disruptor in the field of digital hematology and clinical lab automation, a sector that is ripe for innovation given growing global demand for efficient diagnostic tools.